A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure



Status:Completed
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:21 - 85
Updated:7/27/2018
Start Date:December 2013
End Date:September 2016

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

To evaluate the overall safety and efficacy of TRV027 when administered in addition to
standard of care (SOC) on mortality, morbidity, dyspnea, and length of stay in patients
hospitalized with Acute Decompensated Heart Failure (ADHF).


Inclusion Criteria:

1. Men or women aged ≥21 years and ≤ 85 years 1a.Women of non-child-bearing potential

2. Able to provide written informed consent

3. Pre-existing diagnosis of heart failure and at least 30 days treatment with daily oral
loop diuretics

4. Systolic blood pressure ≥105 mmHg and ≤ 160 mmHg within 30 minutes of randomization

5. Ventricular rate ≤125 bpm. Patients with rate-controlled persistent or permanent
atrial fibrillation (aFib) at screening are permitted.

6. Presence of ADHF defined by:

- BNP > 400 pg/mL or NT-proBNP > 1600 pg/mL

- For patients with BMI >30 kg/m2: BNP > 200 pg/mL or NT-proBNP > 800 pg/mL

- For patients with rate-controlled persistent or permanent aFib: BNP > 600
pg/mL or NT-proBNP > 2400 pg/mL

- Congestion on chest radiograph (CXR)

AND at least two (2) of the following:

- Rales by chest auscultation

- Edema ≥ +1 on a 0-3 + scale, indicating indentation of skin with mild digital
pressure that requires 10 or more seconds to resolve in any dependent area
including extremities or sacral region.

- Elevated jugular venous pressure (≥8 cm H2O)

7. Receipt of a IV loop diuretic at a minimum dose 40 mg furosemide (or equivalent loop
diuretic) for the treatment of dyspnea due to ADHF at least 1 hour prior to
anticipated randomization and the initiation of study medication

8. Patient report of dyspnea at rest or upon minimal exertion during screening at least
one hour after administration of IV loop diuretic

Exclusion Criteria:

1. Women who are pregnant or breast-feeding

2. Clinical presentation:

1. Suspected ACS based on clinical judgment

2. Coronary revascularization in the 3 months prior to screening or planned during
current admission.

3. Temperature >38.5oC

4. Clinically significant anemia

5. Serum sodium >145 mEq/L (145 mmol/L)

6. Current or planned ultrafiltration, paracentesis, hemofiltration or dialysis at
time of screening

7. Any mechanical ventilation

8. CPAP/BiPAP discontinued less than 1 hour prior to randomization

9. History of LVAD or IABP within the last year

10. Intravenous radiographic contrast agent within 72 hours prior to screening or
presence of acute contrast induced nephropathy at the time of screening

11. Presence of clinically significant arrhythmia

12. Uncertainty of ability to complete follow up

3. Medications:

1. nitroprusside or nesiritide

2. Intravenous nitrates

3. use of inotropes

4. Use of ARBs within 7 days of prior to randomization

5. Use of any investigational medication within 30 days

6. clinically significant hypersensitivity or allergy to, or intolerance of,
angiotensin receptor blockers

4. Medical history:

1. Major surgery within 8 weeks prior to screening

2. Stroke within 3 months prior to screening

3. eGFR (sMDRD) <20 mL/min/1.73m2 or >75 mL/min/1.73m2 between presentation and
randomization

4. Post cardiac or renal transplant

5. Listed for renal transplant or cardiac transplant with anticipated transplant
time to transplant < 6 months

6. History of severe left ventricular outlet obstruction (either valvular or
sub-valvular), severe mitral valve stenosis or severe aortic regurgitation

7. Cardiac valvular abnormality that requires surgical correction

8. Complex congenital heart disease

9. Hypertrophic or restrictive cardiomyopathy

10. significant pulmonary or hepatic disease that could interfere with the evaluation
of safety or efficacy of TRV027

11. life expectancy of less than 6 months
We found this trial at
5
sites
5050 Anthony Wayne Dr
Detroit, Michigan 48201
(313) 577-2424
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
2002 Holcombe Blvd
Houston, Texas 77030
(713) 791-1414
Michael E. Debakey VA Medical Center The Michael E. DeBakey VA Medical Center serves as...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Tullahoma, Tennessee 37388
?
mi
from
Tullahoma, TN
Click here to add this to my saved trials